ENCINITAS, Calif., May 09, 2022 (GLOBE NEWSWIRE) — Ventyx Biosciences, Inc. (Nasdaq: VTYX), (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a range of inflammatory diseases with significant unmet medical need, today announced the appointment of William Sandborn, MD, as President and Chief Medical Officer.
“I am delighted to welcome Bill to the Ventyx leadership team,” said Raju Mohan, CEO. “In addition to being an accomplished physician, a world-renowned immunologist and an expert in the field of inflammatory bowel disease, Bill has also played a key role in the development of a number of approved therapies in the immunology space, both small-molecules and biologics. As Chairman of our Clinical Advisory Board, Bill has already played a vital role in developing and shaping our clinical strategy and now, in his new role as both President and CMO, he will lead our clinical development team as we advance our diverse portfolio that targets multiple immune-mediated diseases.”
